Venetoclax

Venetoclax 2D structure
Brand name: Venclexta
IUPAC: 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
FDA approval: Yes
Manufacturer Link
Usage:

Venetoclax is used in the treatment of chronic lymphocytic leukemia and is administered via an oral tablet.1

  • 1Example of VENCLEXTA™ outpatient prophylaxis and monitoring schedule1 (low or medium tumor burden). (n.d.). Retrieved July 05, 2017, from https://www.venclextahcp.com/
Mechanism:

Venetoclax works by targeting the BCL-2 gene, which is responsible for the inhibition of apoptosis.  In addition, the BCL-2 gene is often associated with a Leukemia cell's resistance to chemotherapy.  Venetoclax looks to bring on apoptosis of cancerous cells by mitigating the effect of this BCL-2 gene.1

  • 1VENCLEXTA™: MOA. (n.d.). Retrieved July 05, 2017, from https://www.venclextahcp.com/moa.html?cid=gdc_PS_MBVNCL0009_2&c=MBVNCL0009&gclid=Cj0KEQjwnPLKBRC-j7nt1b7OlZwBEiQAv8lMLKHrTdXKptc_y4l7UQ1hbxKe7iSsw_3klPE9HJXFK40aApMI8P8HAQ
Side effects:

Common side effects in the use of Venetoclax include neutropenia, nausea, upper respiratory issues and fatigue.1

  • 1Example of VENCLEXTA™ outpatient prophylaxis and monitoring schedule1 (low or medium tumor burden). (n.d.). Retrieved July 05, 2017, from https://www.venclextahcp.com/
Contraindications:

Use of Venetoclax in conjunction with a CYP3A inhibitors can cause adverse response and reactions.1

  • 1Example of VENCLEXTA™ outpatient prophylaxis and monitoring schedule1 (low or medium tumor burden). (n.d.). Retrieved July 05, 2017, from https://www.venclextahcp.com/